Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SDGR · against 402 other Healthcare companies of similar size
Ranked #290 of 403 · scores higher than 7% of peers
Bars: peers in each 10-point band of the valuation score114 peers with a valuation score of 0–9, including SDGR · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | SDGR | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 391 reported | -2.7% | 1.7% | 29% | 30% | |
| EBITDA yieldHigher is better · 403 reported | -8.8% | 4.3% | 15% | 50% | |
| Free cash flow yieldHigher is better · 195 reported | -6.4% | -0.4% | 25% | 20% | |
| Book yieldHigher is better · 394 reported | 16.6% | 34.6% | 22% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 290 | 2.4B USD | 8 | 20 | |
| 290 | 1.9B USD | 8 | 18 | |
| 290 | 3.8B USD | 8 | 48 | |
| 290 | 2.0B USD | 8 | 24 | |
| 290 | 2.0B USD | 8 | 26 | |
| 290 | 2.0B USD | 8 | 53 | |
| 290 | 1.2B USD | 8 | 40 | |
| 290 | 1.1B USD | 8 | 50 | |
| 290 | 1.2B USD | 8 | 21 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score